Gilead Sciences Inc. (GILD)
Gilead Sciences Eyes HIV, Oncology Catalysts as Pipeline Enters Execution Mode
Gilead Sciences NASDAQ: GILD Chief Medical Officer Dietmar Berger outlined the company's priorities across HIV, oncology and inflammation at the Wells Fargo conference, describing a portfolio that has expanded through internal development and acquisitions and is now entering a period of prioritization and execution.
Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $146.64, denoting a -2.88% move from the preceding trading day.
Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?
Gilead's quarterly dividend keeps growing and its HIV cash machine runs hot, but the whole enterprise depends on a single blockbuster drug with a patent expiration already penciled onto a calendar a decade out.
Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report?
Gilead (GILD) reported earnings 30 days ago. What's next for the stock?
Can Bixlenvo Unlock New Growth for Gilead's HIV Business?
GILD's FDA approval of Bixlenvo expands its HIV portfolio with a first-of-its-kind single-tablet option for underserved patients.
Gilead (GILD) Upgraded to Strong Buy: What Does It Mean for the Stock?
Gilead (GILD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Wall Street Analysts See Gilead (GILD) as a Buy: Should You Invest?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Gilead Wins FDA Nod for Bixlenvo in Adults Living With HIV Infection
GILD wins FDA approval for Bixlenvo, a once-daily HIV regimen offering a smaller single-tablet option for patients on complex therapies.
FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients
The Food and Drug Administration approved a once-daily HIV pill from Gilead that could help simplify care for some patients whose virus is already under control but who remain on complicated treatment regimens. The tablet combines bictegravir, the backbone of Gilead's blockbuster HIV pill Biktarvy, with lenacapavir, a centerpiece of the company's long-term strategy for HIV treatment and prevention.
EC Approves Label Expansion of GILD's Trodelvy in First-line Metastatic TNBC
Trodelvy's latest EU approval with Keytruda expands its first-line metastatic TNBC use, strengthening Gilead???s oncology growth opportunity.
Is Gilead's Expanding HIV Portfolio a Growth Catalyst?
Gilead's HIV franchise gains momentum as Yeztugo ramps up, Biktarvy leads treatment and new pipeline advances strengthen growth prospects.
Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade)
Gilead's R&D pipeline gained momentum in the first half of 2026, adding several potential growth drivers. Sales of Biktarvy, the flagship of Gilead's HIV franchise, rose 6.9% year-over-year and 12.2% QoQ to ~$3.77 billion in the second quarter. On the other hand, Livdelzi, a PPARδ agonist, generated $167 million in revenue for Gilead, up 114.1% YoY.
